Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 13/20 | 0.38 |
| ▸ | MMP1 | P03956 | 10/20 | 0.38 |
| ▸ | MMP2 | P08253 | 9/20 | 0.38 |
| ▸ | MMP7 | P09237 | 4/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24574406 | 0.95 | CA1 (0.39) | CA1MMP3MMP1MMP2MMP7 | |
| SCHEMBL24360629 | 0.88 | MAPK1 (0.32) | — | |
| SCHEMBL24574563 | 0.85 | MMP3 (0.44) | CA1MMP3MMP1MMP2MMP7 | |
| SCHEMBL24574483 | 0.83 | CA2 (0.47) | CA1MMP3MMP1MMP2MMP7 | |
| SCHEMBL24575165 | 0.81 | CA2 (0.43) | CA1MMP3MMP1MMP2MMP7 | |
| SCHEMBL24360754 | 0.80 | — | — | |
| SCHEMBL351185 | 0.75 | CA1 (0.74) | CA1ACE2CA2FDPSFFAR4 | |
| SCHEMBL3231557 | 0.73 | CA1 (0.71) | CA1ACE2CA2FDPSFFAR4 | |
| SCHEMBL1922411 | 0.73 | CA1 (0.71) | CA1ACE2CA2FDPSFFAR4 | |
| SCHEMBL2710871 | 0.73 | CA1 (0.71) | CA1ACE2CA2FDPSFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-20220125941-A1 | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | POU5F1, POU2F1, POU2F2 | CA1 607/4885ACE2 3822/4885MMP3 1867/4885 |
| US-20220125941-A1 | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof | SHBG, HSD17B7, CYP17A1 | CA1 2329/4885ACE2 4044/4885MMP3 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.